Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Sell $750M in Notes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it would offer $750 million worth of senior notes through two offerings.

The firm has not filed a final prospectus yet on the offerings. However, in a statement, Agilent said that it would use the proceeds to satisfy, in part, the financing obligation of Agilent Technologies World Trade, the subsidiary that acquired Varian for $1.5 billion in May.

Fitch Ratings placed a 'BBB' rating on the proposed notes offering.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.